Send to:

Choose Destination
See comment in PubMed Commons below
ACS Chem Biol. 2012 Nov 16;7(11):1892-901. doi: 10.1021/cb300320d. Epub 2012 Sep 5.

Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents.

Author information

  • 1Department of Molecular Genetics and the Donnelly Centre, University of Toronto, Toronto, ON, M5S3E1 Canada.


Platinum-based drugs have been used to successfully treat diverse cancers for several decades. Cisplatin, the original compound of this class, cross-links DNA, resulting in cell cycle arrest and cell death via apoptosis. Cisplatin is effective against several tumor types, yet it exhibits toxic side effects and tumors often develop resistance. To mitigate these liabilities while maintaining potency, we generated a library of non-classical platinum-acridine hybrid agents and assessed their mechanisms of action using a validated genome-wide screening approach in Saccharomyces cerevisiae and in the distantly related yeast Schizosaccharomyces pombe. Chemogenomic profiles from both S. cerevisiae and S. pombe demonstrate that several of the platinum-acridines damage DNA differently than cisplatin based on their requirement for distinct modules of DNA repair.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society Icon for PubMed Central
    Loading ...
    Write to the Help Desk